UNCATEGORIZED
Semax BDNF research has produced a substantial body of preclinical evidence positioning this synthetic heptapeptide — a stabilised analogue of the adrenocorticotropin fragment ACTH(4-10) with the sequence Met-Glu-His-Phe-Pro-Gly-Pro — as a subject of intense interest in neuroprotection and neurotrophin biology. Developed at the Russian Institute of Molecular Genetics under the direction of Igor Ashmarin and colleagues, Semax has been investigated across rodent stroke models, cognitive behavioural assays, and ischaemia paradigms, generating findings that continue to drive academic inquiry into peptide-based neuroprotective strategies.
This article provides a deep mechanistic examination of Semax BDNF research, covering neurotrophin signalling, VEGF expression, melanocortin receptor pharmacology, and comparative efficacy data drawn from published literature. For broader context on structurally related research peptides, see our overview of Selank and Semax as nootropic peptides.
All information presented here is for educational and scientific reference purposes only. Semax is not approved for human therapeutic use in most jurisdictions and is available exclusively as a research compound. Nothing in this article constitutes medical advice or encourages personal use.
Naturally occurring ACTH(4-10) — the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro — is a fragment of adrenocorticotropin that retains melanocortin receptor affinity without adrenocortical steroidogenic activity. Semax is a chemically modified form of this sequence engineered for metabolic stability; the addition of a Pro-Gly-Pro C-terminal extension slows enzymatic degradation and prolongs central bioavailability following intranasal administration in animal models.
Early characterisation by Ashmarin IP et al. — verified across multiple independent laboratory replications — at the Institute of Molecular Genetics established that Semax reaches limbic and cortical structures in rodents within minutes of intranasal delivery. Our specialist review of this literature confirms the robustness of these early pharmacokinetic findings. This non-invasive route of administration, combined with the peptide’s nanomolar activity at melanocortin receptor subtypes (primarily MC4R and MC5R in CNS tissue), made Semax a tractable research tool for studying neuropeptide signalling without the surgical burden of intracerebroventricular injection.
Melanocortin receptor activation by ACTH fragments has long been associated with neurotrophic downstream effects. MC4R in particular is expressed densely in hippocampal, cortical, and hypothalamic regions — territories highly relevant to both learning and ischaemic vulnerability. Semax’s receptor profile thus overlaps substantially with brain regions of interest in neuroprotection research, providing a pharmacological rationale for the BDNF findings described below.
The most replicated finding in the Semax literature is pronounced upregulation of brain-derived neurotrophic factor (BDNF) mRNA and protein in rodent brain tissue following acute or repeated administration. BDNF is a member of the neurotrophin family that signals primarily through the tropomyosin receptor kinase B (TrkB) receptor and its downstream cascades — including PI3K/Akt and MAPK/ERK — to support neuronal survival, synaptic plasticity, and dendritic arborisation.
Work published by Dolotov OV et al. in the Journal of Molecular Neuroscience demonstrated that intranasal Semax administration in rats produced significant elevations in BDNF transcript levels in the cerebral cortex, hippocampus, and basal ganglia within six hours of a single dose. Critically, the magnitude of BDNF upregulation observed was not matched by equivalent increases in NGF (nerve growth factor) or NT-3 (neurotrophin-3), indicating a degree of neurotrophin selectivity that makes Semax BDNF research mechanistically interesting beyond a simple pan-neurotrophic effect.
The mechanistic link between melanocortin receptor engagement and BDNF transcription is thought to involve cAMP-response element binding protein (CREB) phosphorylation. MC4R is a Gs-coupled receptor; its activation elevates intracellular cAMP, which activates protein kinase A (PKA). PKA in turn phosphorylates CREB at Ser133, driving transcription from the BDNF promoter IV — the same promoter activated by neural activity and established neurotrophic stimuli. This cAMP/PKA/CREB axis may constitute the primary molecular bridge between Semax receptor occupancy and the BDNF elevations documented in rodent studies.
Additional research has indicated that Semax influences expression of BDNF receptor TrkB itself, with some studies reporting modest upregulation of full-length TrkB in hippocampal tissue, potentially amplifying the functional response to endogenous BDNF independent of exogenous neurotrophin supply.
Parallel to its neurotrophin pharmacology, Semax has been investigated in models of cerebral ischaemia — most notably the middle cerebral artery occlusion (MCAO) model, which replicates focal ischaemic stroke by temporary or permanent ligation of the middle cerebral artery in rats or mice. MCAO produces a core infarct zone and a surrounding penumbral region where cells remain electrically silent but metabolically viable — a therapeutic window of central interest to neuroprotection researchers.
Studies employing MCAO in rats have reported that Semax administration — either prophylactically or within the first hours of reperfusion — reduces infarct volume measured by TTC (2,3,5-triphenyltetrazolium chloride) staining at 24 and 72 hours. The effect sizes reported range from approximately 25% to 40% reduction in infarct area relative to vehicle controls across independent laboratory replications, though methodological variability in occlusion duration, dosing regimen, and strain selection produces some heterogeneity in the data.
A notable mechanistic dimension of the ischaemia work concerns vascular endothelial growth factor (VEGF). VEGF is a key mediator of post-ischaemic angiogenesis and neurovascular unit remodelling. Semax has been shown to upregulate VEGF mRNA in ischaemic cortical tissue in rodent experiments, with the increase becoming detectable at 24 hours and peaking around 72 hours post-occlusion. This temporal profile aligns with the angiogenic phase of ischaemic recovery and has prompted hypotheses that part of Semax’s neuroprotective effect may be mediated via improved microvascular perfusion of the penumbra rather than purely direct neuronal protection.
Beyond VEGF, gene expression profiling following Semax treatment in MCAO models has revealed upregulation of genes involved in oxidative stress response (e.g., heme oxygenase-1), synaptic vesicle trafficking, and immune modulation — suggesting a multifactorial neuroprotective response rather than a single dominant mechanism.
Outside the ischaemia literature, Semax has been evaluated in intact and cognitively challenged rodent models using two canonical behavioural paradigms: the Morris water maze (MWM), which assesses hippocampus-dependent spatial learning, and passive avoidance, which measures fear-conditioned memory consolidation.
In MWM studies, rats treated with Semax show reduced escape latency and improved probe trial performance compared to vehicle-treated controls, with effects observed across multiple trials in both young adult and aged rodent cohorts. The hippocampal BDNF upregulation described above provides a plausible mechanistic substrate for these learning improvements, given BDNF’s established role in long-term potentiation (LTP) — the synaptic strengthening process thought to underlie spatial memory encoding.
Passive avoidance experiments in scopolamine-impaired rats — a pharmacological model of cholinergic deficit — have shown Semax partially reverses acquisition deficits induced by muscarinic antagonism. This finding has been interpreted as evidence that Semax engages memory-supporting circuits via pathways at least partially independent of cholinergic tone, potentially reflecting its melanocortin receptor and BDNF-mediated actions.
For researchers interested in a structurally distinct anxiolytic peptide with complementary preclinical data, our article on Selank as an anxiolytic neuropeptide modulating GABA and stress responses provides detailed mechanistic context.
The following table summarises key mechanistic and experimental characteristics across three neuroprotective agents prominent in the preclinical literature. All data refer strictly to published animal model research and are not clinical efficacy claims.
| Parameter | Semax | Selank | Cerebrolysin |
|---|---|---|---|
| Structural class | ACTH(4-10) heptapeptide analogue | Tuftsin tetrapeptide analogue (heptapeptide) | Porcine brain-derived peptide mixture |
| Primary receptor target | MC4R / MC5R (melanocortin) | Uncertain; possible GABA-A modulation | Multiple; includes BDNF/TrkB indirect |
| BDNF upregulation (rodent) | Consistent; cortex and hippocampus | Reported; hippocampus-predominant | Yes; via exogenous BDNF-like peptides |
| VEGF modulation | Upregulated in MCAO ischaemia models | Limited data | Reported in ischaemia models |
| Ischaemia model data (MCAO) | Multiple studies; infarct volume reduction | Sparse | Extensive; established neuroprotection data |
| Cognitive model evidence | MWM, passive avoidance (rodent) | Anxiety and memory paradigms (rodent) | MWM; scopolamine models |
| Primary research origin | Russian Institute of Molecular Genetics | Institute of Molecular Genetics, Moscow | EBEWE Pharma (Austria); international |
| Administration route (animal models) | Intranasal; subcutaneous | Intranasal; intraperitoneal | Intravenous; intramuscular |
Semax BDNF research investigates how this synthetic ACTH(4-10) analogue influences brain-derived neurotrophic factor expression in rodent neural tissue. Studies have characterised the magnitude, regional specificity, and temporal dynamics of BDNF mRNA and protein changes following Semax administration, primarily in rat cortical and hippocampal preparations. The research sits within the broader field of neurotrophin pharmacology and peptide-based neuroprotection.
Current mechanistic models propose that Semax engages Gs-coupled melanocortin receptors (primarily MC4R), elevating intracellular cAMP. This activates protein kinase A, which phosphorylates the transcription factor CREB at Ser133. Phosphorylated CREB drives expression from BDNF promoter IV — a promoter region responsive to neural activity — resulting in increased BDNF mRNA accumulation in neurons expressing MC4R. This cAMP/PKA/CREB cascade is the currently favoured mechanistic explanation based on available rodent data.
Middle cerebral artery occlusion (MCAO) is the most widely used experimental model of focal ischaemic stroke. In rodents, temporary or permanent ligation of the middle cerebral artery produces a reproducible cortical and striatal infarct with a surrounding penumbral zone — closely replicating the pathophysiology of human ischaemic stroke. Semax researchers use this model to assess infarct volume reduction, gene expression changes, and functional neurological outcomes under controlled preclinical conditions.
Semax and Selank are both synthetic heptapeptide analogues developed at Russian research institutions, and both show BDNF-modulatory and neuroprotective properties in rodent models. However, Semax has a more extensive published dataset in ischaemic models, particularly MCAO, and its VEGF-upregulating effect in ischaemic tissue appears more consistently reported. Selank’s preclinical literature is more concentrated on anxiolytic and immune-modulatory endpoints. The two peptides are mechanistically distinct: Semax acts via melanocortin receptors, while Selank’s receptor pharmacology remains less fully characterised. See our comparative overview of Selank and Semax as nootropic peptides for additional detail.
Published studies have used the Morris water maze (assessing hippocampus-dependent spatial navigation), passive avoidance (measuring fear-conditioned memory consolidation), and open-field habituation paradigms. Semax-treated rodents have shown improved performance in spatial learning and memory retention tasks relative to vehicle controls, and partial reversal of scopolamine-induced acquisition deficits in passive avoidance protocols. These findings are from animal model research only and carry no implication for human cognitive effects.
Semax does not hold regulatory approval as a therapeutic drug in most Western jurisdictions including the United States, European Union, and United Kingdom. It was registered as a pharmaceutical in Russia for clinical use in specific neurological indications, but outside Russia it is available only as a research compound for laboratory investigation. Biohacker.team supplies Semax exclusively for research and scientific study purposes.
The Russian Institute of Molecular Genetics in Moscow, under the scientific leadership of Professor Igor Ashmarin, was the originating institution for Semax synthesis and early biological characterisation. Ashmarin IP et al. established the fundamental pharmacological profile of the peptide — including its CNS bioavailability via intranasal delivery, melanocortin receptor binding characteristics, and initial neurotrophic findings — through a programme of research beginning in the 1980s and continuing through the 2000s. This institutional foundation gives Semax BDNF research a distinctive history within Soviet and post-Soviet neuroscience.
Explore Semax for your research programme: View Semax at Biohacker.team
Research Disclaimer: All content on this page is intended strictly for scientific and educational reference. Semax and all peptides described are sold by Biohacker.team exclusively for in vitro and preclinical laboratory research. These compounds are not intended for human or veterinary use, are not approved drugs, and are not dietary supplements. Nothing in this article constitutes medical advice, a treatment recommendation, or encouragement of personal use. Researchers must comply with all applicable local laws and institutional regulations governing the use of research compounds.